Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis

References

• Trinkaus-Randall V, Walsh MT, Steeves S, Monis G, Connors LH, Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol. 2005;166:197–208.
   PubMed Web of Science ®Google Scholar
• Monis GF, Schultz C, Ren R, et al. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am J Pathol. 2006;169:1939–1952.
   Google Scholar
• Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322–1338.
   PubMed Web of Science ®Google Scholar
• Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA. Monoclonal light chain–mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest. 2001;81:689–703.
   PubMed Web of Science ®Google Scholar
• Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84:440–451.
   PubMed Web of Science ®Google Scholar
• Urmoneit B, Prikulis I, Wihl G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest. 1997;77:157–166.
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum. 2002;46:1905–1913.
   Google Scholar
• Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE. Amyloid production in human myeloma stem-cell culture with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med. 1982;307:1689–1692.
   Google Scholar
• Shirahama T, Cohen AS. An analysis of the close relationship of lysosomes to early deposits of amyloid. Am J Pathol. 1973;73:97–114.
   PubMed Web of Science ®Google Scholar
• Shirahama T, Cohen AS. Intralysosomal formation of amyloid fibrils. Am J Pathol. 1975;81:101–116.
   PubMed Web of Science ®Google Scholar
• Itabashi M, Takei T, Tsukada M, et al. Association between clinical characteristics and AL amyloid deposition in the kidney. Heart Vessels. 2010;25:543–548.
   PubMed Web of Science ®Google Scholar
• Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2102;27:1097–1101.
   Google Scholar
• Hopfer H, Wiech T, Mihatsch MJ. Renal amyloidosis revisited: amyloid distribution, Onlydynamics and biochemical type. Nephrol Dial Transplant. 2011;26:2877–2884.
   PubMed Web of Science ®Google Scholar
• Brandt K, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med. 1968;44:955–969.
   PubMed Web of Science ®Google Scholar
• Buja LM, Khoi NB, Roberts WC. Clinically significant cardiac amyloidosis. Clinicopathologic findings in 15 patients. Am J Cardiol. 1970;26:394–405.
   PubMed Web of Science ®Google Scholar
• Gilat T, Revach M, Sohar E. Deposition of amyloid in the gastrointestinal tract. Gut. 1969;10:98.
   PubMed Web of Science ®Google Scholar
• Herskovic T, Bartholomew LG, Green PA. Amyloidosis and malabsorption syndrome. Arch Intern Med. 1964;114:629–633.
   PubMedGoogle Scholar
• Jennette JC, Sheps DS, McNeill DD. Exclusively vascular systemic amyloidosis with visceral ischemia. Arch Pathol Lab Med. 1982 Jul;106:323–327.
   PubMed Web of Science ®Google Scholar
• Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979;44:413–417.
   PubMed Web of Science ®Google Scholar
• Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease from obstructive intramural coronary amyloidosis. Am J Med. 2000;109:181–188.
   PubMed Web of Science ®Google Scholar
• Miani D, Rocco M, Alberti E, Spedicato L, Fioretti PM. Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris. Ital Heart J. 2002;3:479–482.
   PubMedGoogle Scholar
• Barth RF, Willerson JT, Buja LM, Decker JL, Roberts WC. Amyloid coronary artery disease, primary systemic amyloidosis and paraproteinemia. Arch Intern Med. 1970;126:627–630.
   PubMedGoogle Scholar
• James TN. Small arteries of the heart. Circulation. 1977;56:2–14.
   PubMed Web of Science ®Google Scholar
• James TN. Diseases of the large and small coronary arteries. Arch Intern Med. 1974;134:163–176.
   PubMedGoogle Scholar
• James TN. Pathology of small coronary arteries. Am J Cardiol. 1967;20:679–691.
   PubMed Web of Science ®Google Scholar
• Capone R, Amsterdam EA, Mason DT, Zelis R. Systemic amyloidosis, functional coronary insufficiency, and autonomic impairment. Ann Intern Med. 1972;76:599–603.
   PubMed Web of Science ®Google Scholar
• Neben-Wittich MA, Wittich CM, Mueller PS, et al. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118:1287.
   PubMed Web of Science ®Google Scholar
• Cantwell RV, Aviles RJ, Bjornsson J, et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol. 2002;25:33–37.
   PubMed Web of Science ®Google Scholar
• Cueto-Garcia L, Tajik AJ, Kyle RA, Edwards WD, Wood DL, Seward JB. Echocardiographic features of amyloid ischemic heart disease. Am J Cardiol. 1985;55:606–607.
   PubMed Web of Science ®Google Scholar
• Narang R, Chopra P, Wasir HS. Cardiac amyloidosis presenting as ischemic heart disease. Cardiology. 1993;82:294–300.
   PubMed Web of Science ®Google Scholar
• Saltissi S, Kertes PJ, Julian DG. Primary cardiac amyloidosis in a young man presenting with angina pectoris. Br Heart J. 1984;52:233–236.
   PubMedGoogle Scholar
• Pascali E. Diagnosis and treatment of primary amyloidosis. Crit Rev Oncol Hematol. 1995;19:149–181.
   PubMed Web of Science ®Google Scholar
• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898–909.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine. 1975;54:271–299.
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–2060.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58:665–683.
   PubMed Web of Science ®Google Scholar
• Lee G, Foerster J, Lukens J, et al. Wintrobe’s Clinical Hematology, 10th edition. Philadelphia, PA: Lippincott, Williams and Wilkins; 1998; 2705–2724.
   Google Scholar
• Gertz MA, Lacy MG, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004;18:17–37.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med. 1998;91:141–157.
   Google Scholar
• Wisniewski HM, Frackowiak J, Zoltowska A, Kim KS. Vascular β amyloid in Alzheimer disease angiopathy is produced by proliferating and degenerating smooth muscle cells. Amyloid Int J Clin Exp Invest. 1994;1:8–16.
   Web of Science ®Google Scholar
• Frackowiak J, Zoltowska A, Wisniewski HM. Non-fibrillar β-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer’s disease. J Neuropathol Exp Neurol. 1994;53:637–645.
   PubMed Web of Science ®Google Scholar
• Wisniewski HM, Weigel J. β-Amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol. 1994;87:233–241.
   PubMed Web of Science ®Google Scholar
• Wisniewski HM, Frackowiak J, Mazur-Kolecka B. In vitro production of β-amyloid in smooth muscle cells isolated from amyloid angiopathy-affected vessels. Neurosci Lett. 1995;183:120–123.
   PubMed Web of Science ®Google Scholar
• Giampaolo M, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924–1933.
   Google Scholar
• Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis – the archetype of structural and pathogenic variability. J Struct Biol. 2000;130:280–289.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Rev. 2012;26:137–154.
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487–517.
   PubMed Web of Science ®Google Scholar
• Owens GK, Meena KS, Brian WR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(13):767–801.
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.
   PubMed Web of Science ®Google Scholar
• Babaev VR, Bobryshev YV, Stenina OV, Tararak EM, Gabbiani G. Heterogeneity of smooth muscle cells in atheromatous plaque of human aorta. Am J Pathol. 1990;136:1031–1042.
   PubMed Web of Science ®Google Scholar
• Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:812–819.
   PubMed Web of Science ®Google Scholar
• Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014;129:1551–1559.
   PubMed Web of Science ®Google Scholar
• Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci USA. 2003;100:13531–13536.
   PubMed Web of Science ®Google Scholar
• Feil S, Fehrenbacher B, Lukowski R, et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res. 2014;115:662–667.
   PubMed Web of Science ®Google Scholar
• Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2014; 15;6(11):1493–1507.
   PubMed Web of Science ®Google Scholar
• Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int. 2005;68:1590–1603.
   Google Scholar
• Keeling J, Herrera GA. Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc Res Tech. 2008;71:371–379.
   PubMed Web of Science ®Google Scholar
• Migrino RQ, Truran S, Gutterman DD, et al. Human microvascular dysfunction and apoptotic injury by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011;301:H2305–H2312.
   PubMed Web of Science ®Google Scholar
• Truran S, Weising V, Ramirez-Alvarado M, et al. Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury. J Liposome Res. 2014;24(1):69–73.
   PubMed Web of Science ®Google Scholar
• Franco DA, Truran S, Burciu C, et al. Migrino RQ: protective role of clusterin in preserving endothelial function in AL-amyloidosis. Atherosclerosis. 2012;225(1):220–223.
   PubMed Web of Science ®Google Scholar
• McWilliams-Koeppen HP, Foster JS, Hackenbrack N, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLos One. 10(9): e0137716. DOI:10.137/journal.pone.0137716.
   Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854–3858.
   PubMed Web of Science ®Google Scholar
• Marin-Argany M, Lin Y, Misra P, et al. Cell damage in light chain amyloidosis. Fibril internalization, toxicity and cell-mediated seeding. J Biol Chem. 2016;291:19813–19825.
   PubMed Web of Science ®Google Scholar